Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Strategic Expansion into AI-Powered Healthcare Solutions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beigene ADS Representing Ord Shs BGNE

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the... see more

Recent & Breaking News (NDAQ:BGNE)

BeiGene Reports Third Quarter 2020 Financial Results

Business Wire November 5, 2020

BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting

Business Wire November 5, 2020

BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

Business Wire October 6, 2020

Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

PR Newswire September 21, 2020

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

Business Wire September 17, 2020

BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Business Wire September 10, 2020

BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström's Macroglobulinemia

Business Wire September 9, 2020

BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

Business Wire September 4, 2020

BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals

Business Wire August 27, 2020

BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors

Business Wire August 25, 2020

Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China

Business Wire August 24, 2020

BeiGene Reports Second Quarter 2020 Financial Results

GlobeNewswire August 6, 2020

BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress

GlobeNewswire August 5, 2020

Priority Review Granted to BeiGene's New Drug Application of Pamiparib in Ovarian Cancer in China

GlobeNewswire July 27, 2020

Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly's Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

GlobeNewswire July 20, 2020

BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China

GlobeNewswire July 17, 2020

BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering

GlobeNewswire July 15, 2020

BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering

GlobeNewswire July 12, 2020

BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research

GlobeNewswire July 2, 2020

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

GlobeNewswire July 1, 2020